Do you sell Retatrutide?

No, retatrutide isn't approved in the UK yet, so we don't sell it and no UK provider legally can. Below is a quick overview of what it is, where it's at, and answers to the questions we get asked most.

Retatrutide is a new once-weekly weight-loss injection being developed by Eli Lilly. It's a "triple agonist," meaning it targets three hormone receptors at once: GLP-1, GIP, and glucagon.

In Phase 3 trials it has produced the strongest weight-loss results seen in this class of medication so far, with participants losing roughly 24–29% of their body weight over 68–72 weeks.

Retatrutide is still in Phase 3 clinical trials and has not been approved by the MHRA, FDA, or any other regulator. It cannot legally be prescribed or dispensed in the UK.

Mass-market availability is still some way off. We'll update this article and let customers know as soon as a UK launch date becomes clear.

There's no confirmed launch date. Most credible estimates point to late 2027 or 2028 at the earliest, with NHS access following later.

No. Anything sold as "retatrutide" in the UK today is unlicensed and we'd strongly advise against it. The MHRA has already taken action against counterfeit suppliers.

Retatrutide works on three hormone pathways instead of one or two, and has shown larger average weight loss in trials. But Mounjaro and Wegovy are approved, available, and clinically proven, whereas retatrutide is still being tested.

We'll review it as soon as it's approved and share an update with our patients.